GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » Net Margin %

Durect (Durect) Net Margin %

: -53.99% (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Durect's Net Income for the three months ended in Dec. 2023 was $-1.44 Mil. Durect's Revenue for the three months ended in Dec. 2023 was $2.67 Mil. Therefore, Durect's net margin for the quarter that ended in Dec. 2023 was -53.99%.

The historical rank and industry rank for Durect's Net Margin % or its related term are showing as below:

DRRX' s Net Margin % Range Over the Past 10 Years
Min: -323.16   Med: -142.14   Max: -1.93
Current: -323.16


DRRX's Net Margin % is ranked worse than
91.57% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 3.765 vs DRRX: -323.16

Durect Net Margin % Historical Data

The historical data trend for Durect's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => -82.07 [6] => -1.93 [7] => -259.46 [8] => -183.23 [9] => -323.16 )
Durect Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.07 -1.93 -259.46 -183.23 -323.16

Durect Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -315.81 -583.59 -537.29 -172.88 -53.99

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Durect's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durect Net Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Durect's Net Margin % distribution charts can be found below:

* The bar in red indicates where Durect's Net Margin % falls into.



Durect Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Durect's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-27.624/8.548
=-323.16 %

Durect's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.441/2.669
=-53.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Durect  (NAS:DRRX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Durect Net Margin % Related Terms

Thank you for viewing the detailed overview of Durect's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Durect (Durect) Business Description

Traded in Other Exchanges
Address
10260 Bubb Road, Cupertino, CA, USA, 95014
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
Executives
Judith J. Robertson director 10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis director 364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp officer: Chief Financial Officer C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia director ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman officer: Chief Medical Officer C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice officer: Sr. VP Operations & Corp QA 10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg officer: Chief Financial Officer 10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown director, officer: President & CEO 10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105